Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06193889 · ClinicalTrials.gov registry record · Phase 2
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
A Phase 2 study of Myasthenia Gravis and Generalized Myasthenia Gravis, sponsored by Kyverna Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
- 14
- Study locations
NCT06193889 is a Phase 2 study of Myasthenia Gravis and Generalized Myasthenia Gravis that is actively recruiting participants, run by Kyverna Therapeutics. The registered enrollment target is 66 participants, below the 189-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (65% lower). The trial reports 14 study locations across 7 states.
The verdict
NCT06193889, a Phase 2 study of Myasthenia Gravis and Generalized Myasthenia Gravis, is actively recruiting participants, sponsored by Kyverna Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
- 14
- Study locations
Study Summary
A Study of the Anti-CD 19 Chimeric Antigen Receptor T Cell Therapy for Patients with Myasthenia Gravis
Conditions Studied
Interventions
- DRUG Standard lymphodepletion regimen
- DRUG Standard of Care Treatment
- BIOLOGICAL KYV-101
Study Locations (14)
Other
- Hospital Israelita Albert Einstein - São Paulo
- Charite- Universitätsklinikum Berlin - Berlin
- Universitätsklinikum der Ruhr-Universität Bochum - Bochum
- Universitätsklinikum Hamburg-Eppendorf - Hamburg
- Medizinische Hochscule Hannover - Hanover
- Friedrich-Schiller-Universität Jena - Jena
- Universitätsklinik Magdeburg - Magdeburg
California
- University of California, Irvine - Orange
- Stanford University Medical Center - Palo Alto
Florida
- University of Miami - Miami
Indiana
- Indiana University Health - Indianapolis
Pennsylvania
- Thomas Jefferson University Hospital - Philadelphia
Texas
- Houston Methodist Hospital - Houston
Utah
- Intermountain Medical Center - Murray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2024-08-28 |
| Est. Completion | 2028-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06193889
The ClinicalTrials.gov registry entry for NCT06193889 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 189-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (65% lower). The listed sponsor is Kyverna Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Myasthenia Gravis appearing as the primary indexed condition, and to 3 interventions - of which Standard lymphodepletion regimen is the first listed.
NCT06193889 reports 14 study locations spanning 7 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06193889 about?
NCT06193889 is a clinical study titled "KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis". A Study of the Anti-CD 19 Chimeric Antigen Receptor T Cell Therapy for Patients with Myasthenia Gravis
What is the current status of trial NCT06193889?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2024-08-28. Estimated completion is 2028-09.
What conditions does trial NCT06193889 study?
This clinical trial studies the following conditions: Myasthenia Gravis, Generalized Myasthenia Gravis.
What interventions are being tested in trial NCT06193889?
The interventions under investigation include: Standard lymphodepletion regimen (DRUG), Standard of Care Treatment (DRUG), KYV-101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06193889?
This trial is sponsored by Kyverna Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06193889 being conducted?
This trial has 14 study locations across California, Florida, Indiana, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myasthenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
RECRUITING · Phase 2
-
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
RECRUITING · Phase 2
-
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
RECRUITING · Phase 2
-
BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis
COMPLETED · Phase 2
-
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
COMPLETED · Phase 2
-
A Study of RVT-1401 in Myasthenia Gravis (MG) Patients
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.